CytoMed Therapeutics Limited (GDTC) Stock Forecast
GDTC analyst forecast
as of October 17, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 1 analysts
- Price target
- $4.16 average of analyst targets
- Upside to target
- +372.7% from the latest close
- Next earnings
- —
- 52-week range
- $0.72 – $2.69
GDTC analyst ratings
1 analystsNumber of analysts at each rating.
GDTC price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
GDTC earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Next fiscal year (2026) | $0.00 | $0.00 | $0.00 | −$0.17 | — | — |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
GDTC revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Next fiscal year (2026) | $0 | $0 | $0 | — | — |
GDTC EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
GDTC EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Next fiscal year (2026) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — | 0 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
GDTC earnings surprises
Reported EPS vs the consensus estimate for the last 10 quarters; GDTC beat in 6 of 10.
What analysts expect from GDTC
1 analysts cover CytoMed Therapeutics; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $4.16, 372.7% above the latest close of $0.88. For 2026 the average estimate is $0.00 per share. CytoMed Therapeutics beat the EPS estimate in 6 of the last 10 quarters.
Related: GDTC income statement, GDTC key metrics, GDTC chart. See the GDTC stock overview for the latest quote and news.
GDTC forecast FAQ
What is CytoMed Therapeutics's price target?
The average analyst price target for CytoMed Therapeutics is $4.16, 372.7% above the latest close of $0.88.
Is CytoMed Therapeutics a buy, hold or sell?
Of 1 analysts covering CytoMed Therapeutics, 1 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
Does CytoMed Therapeutics usually beat earnings estimates?
CytoMed Therapeutics reported EPS at or above the analyst estimate in 6 of the last 10 quarters.